If your body changed shape in your late 40s and 50s — weight settling around your middle even though you eat and move much as you always have. Does this sound like you? You are not alone.
As estrogen falls, fat redistributes toward the abdomen, lean muscle mass begins to decline, and metabolic rate drops. It is physiology, not a failure of willpower. It is also why GLP-1 medicines — the class that includes semaglutide and tirzepatide — come up in so many menopause conversations now. So what does the research actually show, specifically in menopausal women?
What the studies found
The honest starting point: the big GLP-1 trials were general obesity trials, not menopause trials. They included midlife women, and weight loss in those trials was substantial, but they were not designed to answer menopause-specific questions. The menopause-specific evidence is newer and smaller. The study most often cited is a Mayo Clinic cohort published in the journal Menopause in 2024 (Hurtado and colleagues): researchers followed 106 postmenopausal women treated with semaglutide for overweight or obesity, and compared those also using hormone therapy with those who were not. At 12 months, the hormone-therapy group had lost about 16% of their body weight, versus about 12% in the group on semaglutide alone — a difference that held at every check-in from three months onward. That is a genuinely interesting result, and it fits the biology: if estrogen loss is part of what drives menopause weight gain, treating both pathways may do more than treating one. But interesting is not the same as proven — see the rigor note below before quoting that 16% anywhere.
What is still unknown
Menopause-specific trials. No randomized trial has yet tested GLP-1 medicines specifically in menopausal women, or tested the GLP-1-plus-hormone-therapy combination head-to-head.
Symptoms. GLP-1s are not a treatment for hot flashes or night sweats, and they do not replace hormone therapy where hormone therapy is indicated. They address weight and metabolic risk — a different job.
Muscle and bone. Weight lost on these medicines includes lean mass as well as fat, at an age when muscle and bone are already declining. Protein, resistance training and bone health belong in any GLP-1 conversation in menopause — not as an afterthought.
Staying on them. Nausea and other gut side effects are common, the medicines are long-term rather than a short course, and weight commonly returns after stopping. Cost and coverage vary widely.
So, should every woman in menopause be on one? No — and that is not what the research says. What it says is narrower and more useful: for postmenopausal women with overweight or obesity, GLP-1 treatment produced meaningful weight loss in the data we have, hormone therapy may add to that effect, and the decision deserves a real conversation about muscle, bone, symptoms and the long term — not a headline. Those conversations are a standing topic in The Modern Woman Community's wellness programming and monthly live Q&As, including sessions with Melanie Zavala, APRN, our board-certified Menopause Society provider, where members can ask exactly these questions.
Hurtado et al., Menopause, 2024 was a retrospective cohort — medical records reviewed after the fact, not a randomized trial. Only 106 women were included, the hormone-therapy group was small, and women who choose hormone therapy differ from women who do not in ways a records review cannot fully adjust for. The 16% vs 12% result is an association and a reason for proper trials, not proof that hormone therapy boosts GLP-1 weight loss. Nothing in this post is a recommendation to start, stop or combine medicines.